Lincoln Pharmaceuticals has received approval from Australia's medicines and medical devices regulator - Therapeutic Goods Administration (TGA). The company's manufacturing facility in Khatraj, Gujarat received the GMP clearance from TGA for all three departments Tablet, Capsule and Cream & Ointment, which will cover wide range of Pharmaceutical Formulation manufactured by the Company. Company looks to enter the Australian markets soon with its dermatology, gastro and pain management products and gradually expand product portfolio. The certification will be valid till June 2023.
TGA and EU GMP approval will strengthen company's presence in the regulated markets. In May 2020, company had received European Union (EU) GMP certification from Germany FDA for its manufacturing facility which allows the company to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries.
The company manufactures wide-range of drugs at its Khatraj facility and includes anti-infective, respiratory system, gynaecology, dermatology, gastro, pain management, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.
Lincoln Pharmaceuticals is engaged in the manufacture and marketing of affordable therapeutic products.
